Mon, Jul 28, 2014, 11:41 AM EDT - U.S. Markets close in 4 hrs 19 mins


% | $
Click the to save as a favorite.

Idenix Pharmaceuticals Inc. Message Board

  • myprimitivesistas myprimitivesistas Apr 15, 2013 8:25 PM Flag

    This is simply the best investment I have ever seen


    Gilead will settle. Its all about the 2'methyl!!!

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • on what basis do you say this ?

      • 1 Reply to giguy_1999
      • littlecatguy Apr 20, 2013 3:59 AM Flag

        Good question with no answer. Idenix now junior party, bearing the burden of proof is costly and risky. They would be better off desisting and investing precious stockholders money in the development of their own pipeline. Doesn´t look like they have enough cash until 2016, are they planning another dilution?

        Transcript from Biopharm Insight "Idenix seen as unlikely to prevail against Gilead in HCV patent interference"
        "Idenix Pharmaceuticals (NASDAQ:IDIX) faces an uphill battle to sufficiently demonstrate enablement in
        its ongoing patent interference against Gilead Sciences (NASDAQ:GILD) regarding their respective
        hepatitis C (HCV) intellectual property, attorneys said. Idenix is ultimately unlikely to prevail on the
        interference, they noted.
        - Elapsed time to demonstrate diligence, reduction to practice a major hurdle
        - Gilead’s senior party status likely to trump all
        -Idenix must submit brief on priority by 26 April, failure will lead to Gilead’s win.
        "The decision from the Board of Patent Appeals and Interferences validates Gilead’s perspective that we
        were the first to invent the compounds involved in the interference, as described in the ‘572 patent,” a
        Gilead spokesperson commented. Idenix declined to comment.

24.343+0.013(+0.05%)11:40 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.